Home | Business News | Browse by Publication | P | Pharma Marketletter

AMDL proceeds with Chinese acqusitions.

Publication: Pharma Marketletter
Publication Date: 16-JAN-06
Format: Online
Delivery: Immediate Online Access
Full Article Title: AMDL proceeds with Chinese acqusitions.(Brief Article)

Article Excerpt
AMDL, a US developer and marketer of tests for the early detection of cancer and other serious diseases, says that it is continuing due diligence with Jade Capital Group for the acquisition of Jiangxi Jade Biochemistry Pharmacy and Yangbian Yiqiao Biochemistry Pharmacy previously announced last November. Financial statements are...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
Axis-Shield and DPC sign RA diagnostic accord.(Diagnostic Products Cor..., January 16, 2006
Avalon's AVN944 enters Ph I.(Avalon Pharmaceuticals Inc.)(Brief Articl..., January 16, 2006
Medarex and PharmAthene's Valortim gains fast track status.(Brief Arti..., January 16, 2006
Zonagen gets IRB appro for Ph III Androxal trial.(Investigational Revi..., January 16, 2006
EMEA expects 47 Rx marketing apps this year, as agency responsibilitie..., January 16, 2006

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.